Skip to Content

TG Therapeutics Inc TGTX

Morningstar Rating
$17.65 +0.67 (3.95%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TGTX is trading within a range we consider fairly valued.
Price
$17.72
Fair Value
$22.35
Uncertainty
Very High
1-Star Price
$27.33
5-Star Price
$96.92
Economic Moat
Gjyx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TGTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$16.98
Day Range
$16.8718.34
52-Week Range
$6.4626.95
Bid/Ask
$17.71 / $17.93
Market Cap
$2.73 Bil
Volume/Avg
6.0 Mil / 3.0 Mil

Key Statistics

Price/Earnings (Normalized)
17.64
Price/Sales
9.15
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
264

Comparables

Valuation

Metric
TGTX
ALVR
ALDX
Price/Earnings (Normalized)
17.64
Price/Book Value
17.040.711.82
Price/Sales
9.15
Price/Cash Flow
32.02
Price/Earnings
TGTX
ALVR
ALDX

Financial Strength

Metric
TGTX
ALVR
ALDX
Quick Ratio
2.7618.386.14
Current Ratio
3.6218.486.50
Interest Coverage
4.45−17.02
Quick Ratio
TGTX
ALVR
ALDX

Profitability

Metric
TGTX
ALVR
ALDX
Return on Assets (Normalized)
27.97%−52.15%−17.68%
Return on Equity (Normalized)
73.42%−65.46%−21.58%
Return on Invested Capital (Normalized)
42.25%−59.04%−22.95%
Return on Assets
TGTX
ALVR
ALDX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WswvtprmfZksn$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
QlbglcfcWmtfws$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
GwvlzzfyyLnzpsbb$116.0 Bil
Moderna Inc
MRNA
SktgzvhNwhd$51.1 Bil
argenx SE ADR
ARGX
FsbmjsrpCqztr$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
ClfggtdxKjzcc$21.0 Bil
BioNTech SE ADR
BNTX
QvsbnhsJgsny$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
NqlqpkhBwvqwvw$15.9 Bil
United Therapeutics Corp
UTHR
YfwchffpyMbl$14.0 Bil
Incyte Corp
INCY
FzdscjgsFfnbgh$12.5 Bil

Sponsor Center